$COGT News

Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Cogent Biosciences Says FDA Accepts NDA For Bezuclastinib In Combination With Sunitinib For Patients With GIST With PDUFA Target Action Date Of November 30

HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55

Cogent Biosciences Q1 EPS $(0.53) Beats $(0.56) Estimate

Cogent Biosciences Inc (NASDAQ:COGT) Shows Bullish Technical Breakout Setup with High Scores

Cogent Biosciences Announces That Results From Its Phase 3 PEAK Trial Have Been Selected For Oral Presentation At The 2026 American Society Of Clinical Oncology Annual Meeting, May 29-June 2

Cogent Biosciences Announces That Results From Its Phase 3 PEAK Trial Have Been Selected For Oral Presentation At The 2026 American Society Of Clinical Oncology Annual Meeting, May 29-June 2

Cogent Biosciences Announces Poster Presentations Of Preclinical Data From The KRAS And ErbB2 Pipeline Programs At The American Association For Cancer Research Meeting, April 17-22

Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy'

Cogent Biosciences shares are trading lower. The company announced the completion of the submission of its NDA to the FDA for bezuclastinib in patients with Gastrointestinal Stromal Tumors.

Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Patients With Gastrointestinal Stromal Tumors

Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Cogent Biosciences shares are trading higher after the company announced that the FDA approved its new drug application for bezuclastinib in patients with nonAdvanced systemic mastocytosis.

FDA Accepts Cogent Biosciences' New Drug Application For Bezuclastinib In Patients With NonAdvanced Systemic Mastocytosis

Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug - Still Bullish

Reported Saturday, Cogent Biosciences Highlights SUMMIT Data At AAAAI 2026, Bezuclastinib Delivers –32.0 Point Mean TSS Reduction At 48 Weeks With 99% Achieving ≥50% Serum Tryptase Reduction

Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $52

Cogent Biosciences Q4 EPS $(0.61) Misses $(0.53) Estimate

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

Cogent Biosciences FDA Milestones Put Bezuclastinib And Valuation In Focus